{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:34:13Z","timestamp":1760189653039},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To provide an overview of recently published work on autologous hematopoietic stem-cell transplantation (HSCT) in patients with systemic sclerosis (SSc).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Superiority of HSCT vs. intravenous cyclophosphamide pulses was demonstrated in the randomized controlled American Scleroderma: Cyclophosphamide or Transplantation (SCOT) Trial (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a75), supporting the results from earlier studies. In the SCOT Trial, total body irradiation was used instead of the nonmyeloablative regimens used in other trials, and considered well tolerated during a follow-up time of 4.5 years. Three small uncontrolled prospective cohorts (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a4, 14 and 18) and one retrospective analyses (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a18), using various nonmyeloablative regimens, also showed improvement in skin involvement and lung volumes post-HSCT. Transplant-related toxicity and mortality remain an essential issue in HSCT. High treatment-related mortality was reported in one prospective cohort (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a18), using alemtuzumab as a conditioning agent. Furthermore, cardiac complications, either treatment or disease related, require special attention. In translational studies, trends are reported in number of regulatory T cells and diversity of T-cell receptor repertoire at baseline and post-HSCT correlating with treatment response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>There is increasing evidence that patients with rapidly progressive SSc may benefit from HSCT. However, optimal patient selection, pretransplantation workup and posttransplant management, still have to be established.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000541","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T04:18:34Z","timestamp":1533097114000},"page":"541-547","source":"Crossref","is-referenced-by-count":13,"title":["Hematopoietic stem-cell transplantation in systemic sclerosis: an update"],"prefix":"10.1097","volume":"30","author":[{"given":"Julia","family":"Spierings","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Femke C.C.","family":"van Rhijn-Brouwer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology"},{"name":"Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob M.","family":"van Laar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","article-title":"Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases","volume":"1","author":"Snowden","year":"2017","journal-title":"Blood Adv"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R3-20230901","first-page":"17","article-title":"Consensus-based recommendations on autologous hematopoietic stem cell transplantation in poor prognosis diffuse cutaneous systemic sclerosis","volume":"3","author":"van Rhijn-Brouwer","year":"2016","journal-title":"Ned Tijdschr Reumatol"},{"issue":"(12S)","key":"R4-20230901","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/j.bulcan.2017.06.019","article-title":"Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"104","author":"Pugnet","year":"2017","journal-title":"Bull Cancer"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","article-title":"BSR and BHPR guideline for the treatment of systemic sclerosis","volume":"55","author":"Denton","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous nonmyeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/rheumatology\/keq414","article-title":"Analysis of immune reconstitution after autologous CD34+ stem\/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells","volume":"50","author":"Tsukamoto","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R9-20230901","first-page":"451","article-title":"Analysis of antitopoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation","volume":"56","author":"Henes","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20230901","article-title":"Molecular recognition patterns of antitopoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation","author":"Glaeser","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"(Suppl 104)","key":"R11-20230901","first-page":"11","article-title":"Thymic findings before and after autologous stem cell transplantation for severe systemic sclerosis: a retrospective study using computed tomography in the pre and posttransplantation setting","volume":"35","author":"Henes","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.clim.2004.07.006","article-title":"Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)","volume":"113","author":"Storek","year":"2004","journal-title":"Clin Immunol"},{"key":"R13-20230901","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-018-0162-0","article-title":"Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis","author":"Arruda","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-016-0388-5","article-title":"Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients","volume":"10","author":"Farge","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/bloodadvances.2017011072","article-title":"Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients","volume":"2","author":"Arruda","year":"2018","journal-title":"Blood Adv"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.imlet.2017.11.005","article-title":"Autologous hematopoietic stem cell transplantation in systemic sclerosis: a reset to tolerance?","volume":"195","author":"van Rhijn-Brouwer","year":"2018","journal-title":"Immunol Lett"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/1756-185X.13262","article-title":"Stem cell transplant in systemic sclerosis: an Indian experience","volume":"21","author":"Nair","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"R18-20230901","first-page":"1","article-title":"Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy","author":"Nakamura","year":"2018","journal-title":"Mod Rheumatol"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s10067-017-3954-5","article-title":"Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis","volume":"37","author":"Helbig","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bmt.2016.211","article-title":"Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis","volume":"52","author":"Del Papa","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"R22-20230901","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2018.01.020","article-title":"Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis","volume":"24","author":"Shouval","year":"2018","journal-title":"Blood Marrow Transplant"},{"issue":"(Suppl 106)","key":"R23-20230901","first-page":"198","article-title":"Autologous stem cell transplantation in systemic sclerosis: a systematic review","volume":"35","author":"Host","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"R24-20230901","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjd.15993","article-title":"Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of literature","volume":"178","author":"Eyraud","year":"2018","journal-title":"Br J Dermatol"},{"key":"R25-20230901","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/bmt.2017.188","article-title":"Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening","volume":"52","author":"Martin","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(12)62114-X","article-title":"Cardiac involvement and treatment-related mortality after nonmyeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis","volume":"381","author":"Burt","year":"2013","journal-title":"Lancet"},{"key":"R27-20230901","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2017.56","article-title":"Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners","volume":"52","author":"Farge","year":"2017","journal-title":"Bone Marrow Transplant"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201811000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T01:17:03Z","timestamp":1693531023000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201811000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000541","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}